Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$7.28 USD
+0.32 (4.60%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $7.27 -0.01 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATNM 7.28 +0.32(4.60%)
Will ATNM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ATNM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATNM
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
ATNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar?
Other News for ATNM
Buy Rating Reiterated for Actinium Pharmaceuticals Amid Promising AML Therapy Developments
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Syndax Pharmaceuticals (SNDX)
Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Actinium Pharmaceuticals presents data on Actimab-A in AML
Iomab-B Shows Promising Efficacy in r/r AML: Analyst Endorses Actinium Pharmaceuticals Following EHA Congress Data